Dynamic Forecasting of Cross-Sector Collateral Impact and Consequences of Policy Through Analysis of Live Physical World Data and Events in...

Diversis Capital Acquires LTi Technology Solutions to Accelerate Innovation in Equipment Finance Technology

Traverse Bay Farms Featured in PushOwl Article on Shopify Loyalty Programs

Ridgepost Capital Announces Retirement of Mark Hood as EVP and CAO

Leading DC/Maryland Practice Expands Access to Premium, On-Demand Remote Pregnancy Monitoring with INVU™

BridgeBio to Present Long-Term Efficacy and Safety Data from the ATTRibute-CM OLE Trial at the ACC Annual Scientific Sessions

EndoCyclic Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for ENDO-205, a First-in-Class Non-Hormonal...

Arbutus Reports Fourth Quarter and Year End 2025 Financial Results and Provides Corporate Update

GateKeeper to Showcase Proximity MFA at Manufacturing IT/OT Summit 2026, Delivering Seamless Security for Smart Factories

Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results

HyBryte™ Treatment Results to be Presented at US Cutaneous Lymphoma Consortium Annual Workshop 2026

Cognition Therapeutics to Report Fourth Quarter and Year End 2025 Financial Results

TE Connectivity survey: Return on investment becomes top priority as AI age evolves

SL Green Realty Corp. Announces Annual Ordinary Dividend of $2.47 per Share

FuelCell Energy Scales Up for Data Centers with Packaged 12.5 MW Utility‑Grade Power Block Solution and Manufacturing Expansion Plans

Cabaletta Bio Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Bombardier Announces Successful Completion of Consent Solicitation with Respect to its 7.450% Notes due 2034

Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851

Palvella Therapeutics Strengthens Leadership Team with Appointment of Rare Disease Commercial Leader Jennifer J. McDonough as Senior Vice...

Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation...